首页> 美国卫生研究院文献>Drug Metabolism and Disposition >CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 25-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime
【2h】

CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 25-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime

机译:CYP4F酶是人肝微粒体中主要酶可催化抗寄生虫前药DB289 25-双(4-ami基苯基)呋喃-双-O-甲基ami肟的O-去甲基化。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

DB289 [2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime] is biotransformed to the potent antiparasitic diamidine DB75 [2,5-bis(4-amidinophenyl) furan] by sequential oxidative O-demethylation and reductive N-dehydroxylation reactions. Previous work demonstrated that the N-dehydroxylation reactions are catalyzed by cytochrome b5/NADH-cytochrome b5 reductase. Enzymes responsible for catalyzing the DB289 O-demethylation pathway have not been identified. We report an in vitro metabolism study to characterize enzymes in human liver microsomes (HLMs) that catalyze the initial O-demethylation of DB289 (M1 formation). Potent inhibition by 1-aminobenzotriazole confirmed that M1 formation is catalyzed by P450 enzymes. M1 formation by HLMs was NADPH-dependent, with a Km and Vmax of 0.5 μM and 3.8 nmol/min/mg protein, respectively. Initial screening showed that recombinant CYP1A1, CYP1A2, and CYP1B1 were efficient catalysts of M1 formation. However, none of these three enzymes was responsible for M1 formation by HLMs. Further screening showed that recombinant CYP2J2, CYP4F2, and CYP4F3B could also catalyze M1 formation. An antibody against CYP4F2, which inhibited both CYP4F2 and CYP4F3B, inhibited 91% of M1 formation by HLMs. Two inhibitors of P450-mediated arachidonic acid metabolism, HET0016 (N-hydroxy-N′-(4-n-butyl-2-methylphenyl)formamidine) and 17-octadecynoic acid, effectively inhibited M1 formation by HLMs. Inhibition studies with ebastine and antibodies against CYP2J2 suggested that CYP2J2 was not involved in M1 formation by HLMs. Additionally, ketoconazole preferentially inhibited CYP4F2, but not CYP4F3B, and partially inhibited M1 formation by HLMs. We conclude that CYP4F enzymes (e.g., CYP4F2, CYP4F3B) are the major enzymes responsible for M1 formation by HLMs. These findings indicate that, in human liver, members of the CYP4F subfamily biotransform not only endogenous compounds but also xenobiotics.
机译:DB289 [2,5-双(4-ami基苯基)呋喃-双-O-甲基ami胺肟]通过顺序氧化O-脱甲基和还原性N被生物转化为有效的抗寄生二diDB75 [2,5-双(4-ami基苯基)呋喃]。 -脱羟基反应。以前的工作表明N-脱羟基反应是由细胞色素b5 / NADH-细胞色素b5还原酶催化的。尚未发现负责催化DB289 O-去甲基化途径的酶。我们报告了一项体外代谢研究,以表征人肝微粒体(HLM)中的酶,该酶催化DB289(M1形成)的初始O-去甲基化。 1-氨基苯并三唑的有效抑制作用证实M1的形成是由P450酶催化的。 HLM形成的M1是NADPH依赖性的,Km和Vmax分别为0.5μM和3.8 nmol / min / mg蛋白。初步筛选显示重组CYP1A1,CYP1A2和CYP1B1是M1形成的有效催化剂。但是,这三种酶均不能引起HLM形成M1。进一步的筛选显示重组CYP2J2,CYP4F2和CYP4F3B也可以催化M1的形成。一种同时抑制CYP4F2和CYP4F3B的CYP4F2抗体可抑制HLM形成M1的91%。两种P450介导的花生四烯酸代谢抑制剂HET0016(N-羟基-N'-(4-正丁基-2-甲基苯基)甲idine)和17-十八碳烯酸可有效抑制HLM形成M1。用依巴斯汀和针对CYP2J2的抗体进行的抑制研究表明CYP2J2不参与HLM的M1形成。此外,酮康唑优先抑制CYP4F2,而不抑制CYP4F3B,并部分抑制HLMs形成M1。我们得出结论,CYP4F酶(例如CYP4F2,CYP4F3B)是负责HLM形成M1的主要酶。这些发现表明,在人肝中,CYP4F亚家族的成员不仅内源性化合物而且还异源生物发生生物转化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号